Karen M. Anderson net worth and biography

Karen Anderson Biography and Net Worth

Chief People Officer of Centessa Pharmaceuticals

Karen Anderson joined Centessa in November 2022 as Chief People Officer. Karen has over 25 years of experience in human resources roles spanning the biotechnology/pharmaceutical, technology, and healthcare industries.

Prior to joining Centessa, Karen was Chief Human Resources Officer at Mimecast Limited. Previously, she was Senior Vice President and Chief Human Resources Officer at Alnylam Pharmaceuticals where she supported the strategic direction and business growth from a few hundred employees to more than 1,000 employees in 16 global legal entities. Karen was also Vice President of Human Resources at Pfizer, supporting the Commercial business unit in both developed and emerging markets. Earlier in her career she was responsible for compensation, benefits, and systems for Bayer Canada before becoming the Global Human Resources Director for Baxter where she had a strong focus on mergers and acquisitions.

Karen holds a Masters in Organization Development and Psychology.

What is Karen M. Anderson's net worth?: The estimated net worth of Karen M. Anderson is at least $1.68 million as of March 16th, 2026. Ms. Anderson owns 62,085 shares of Centessa Pharmaceuticals stock worth more than $1,680,020 as of March 21st. This net worth evaluation does not reflect any other investments that Ms. Anderson may own. Learn More about Karen M. Anderson's net worth.
How old is Karen M. Anderson?: Ms. Anderson is currently 56 years old. Learn More on Karen M. Anderson's age.
How do I contact Karen M. Anderson?: The corporate mailing address for Ms. Anderson and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on Karen M. Anderson's contact information.
Has Karen M. Anderson been buying or selling shares of Centessa Pharmaceuticals?: During the last ninety days, Karen M. Anderson has sold $5,260,074.83 in Centessa Pharmaceuticals stock. Most recently, Karen M. Anderson sold 10,043 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $28.10, for a transaction totalling $282,208.30. Following the completion of the sale, the insider now directly owns 62,085 shares of the company's stock, valued at $1,744,588.50. Learn More on Karen M. Anderson's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Mario Accardi (President of the Orexin Program), Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), Arjun Goyal (Director), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, Centessa Pharmaceuticals insiders bought shares 2 times. They purchased a total of 462,585 shares worth more than $5,866,686.94. In the last year, insiders at the sold shares 33 times. They sold a total of 776,681 shares worth more than $16,486,099.78. The most recent insider tranaction occured on March, 17th when insider Karen M Anderson sold 10,043 shares worth more than $282,208.30. Insiders at Centessa Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 3/17/2026.

Karen M. Anderson Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2026	Sell	10,043	$28.10	$282,208.30	62,085
3/16/2026	Sell	64,768	$28.21	$1,827,105.28	62,085
3/13/2026	Sell	120,029	$26.25	$3,150,761.25	62,085
2/10/2025	Sell	429	$18.99	$8,146.71	54,322
2/7/2025	Sell	30,526	$19.03	$580,909.78	54,322
2/3/2025	Sell	6,471	$16.86	$109,101.06	54,322
12/17/2024	Sell	10,624	$17.32	$184,007.68	71,525
12/13/2024	Sell	5,876	$17.01	$99,950.76	71,525
3/25/2024	Sell	51,160	$11.88	$607,780.80	71,525

Karen M. Anderson Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $27.06

$26.72

$28.75

50 Day Range

MA: $25.26

$22.02

$28.95

2 Week Range

Now: $27.06

$9.60

$30.58

Volume

573,489 shs

Average Volume

1,244,146 shs

Market Capitalization

$3.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Karen Anderson Biography and Net Worth

What is Karen M. Anderson's net worth?

How old is Karen M. Anderson?

How do I contact Karen M. Anderson?

Has Karen M. Anderson been buying or selling shares of Centessa Pharmaceuticals?

Who are Centessa Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Centessa Pharmaceuticals?